Diseases and Conditions

The nonclinical drug candidates that Akros Pharma takes into clinical development come out of the research conducted by the Central Pharmaceutical Research Institute (CPRI) of JT Pharmaceuticals in Osaka, Japan. The current development focus for Akros reflects the research focus at CPRI.

Currently, CPRI and Akros are working to develop new therapeutics for the following disease states:

Code
(Generic Name)
Potential IndicationDosage formMechanismStage
JTZ-951
(enarodustat)
  • Anemia associated with chronic kidney disease
OralHIF-PH inhibitorIncreases red blood cells by stimulating production of erythropoietin, an erythropoiesis-stimulating hormone, via inhibition of HIF-PH.Phase1
JTE-051
  • Autoimmune diseases
  • Allergic diseases
OralInterleukin-2 inducible

T cell kinase inhibitor

Suppresses overactive immune response via inhibition of the signal to activate T cells related to immune response.Phase2
JTT-251
  • Type 2 diabetes mellitus
OralPDHK inhibitorDecreases blood glucose by activation of pyruvate dehydrogenase (PDH) related to carbohydrate metabolism.Phase1
JTE-451
  • Autoimmune diseases
  • Allergic diseases
OralRORγ antagonistSuppresses overactive immune response via inhibition of RORγ related to Th17 activation.Phase2
JTT-662
  • Type 2 diabetes mellitus
OralSGLT1 inhibitorSuppresses postprandial hyperglycemia and normalizes blood glucose level via inhibition of SGLT1Phase1
JTE-761
  • Autoimmune diseases
  • Allergic diseases
OralRORγ antagonistSuppresses overactive immune response via inhibitation of RORγ related to Th 17 activationPhase1

Clinical trial phase presented above is based on the first dose.